Back to search
FDAFDA · Food and drugs·Recall number D-0105-2021

DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05

Published December 2, 2020 · Recall initiated: November 17, 2020

Summary

FDA records drug Class III recall D-0105-2021, published December 2, 2020 and initiated November 17, 2020. Recalling firm: Fresenius Kabi USA, LLC; Status: Terminated; Reported quantity: 16,986 vials; Lot: Batch: 6120525, exp 11/2020. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross Contamination with Other Products: trace amounts of octreotide found during testing

What to do

Voluntary: Firm initiated · Letter

Get an email if DOXORUBICIN HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DOXORUBICIN HYDROCHLORIDE
Manufacturer
Fresenius Kabi USA, LLC
Distributor
Nationwide USA and Puerto Rico
Lot
Batch: 6120525, exp 11/2020
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05 recalled?

Yes. FDA published recall D-0105-2021 on December 2, 2020. Reported hazard: Cross Contamination with Other Products: trace amounts of octreotide found during testing

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DOXORUBICIN HYDROCHLORIDE.